ROSS BRUCE S.,SOFIA MICHAEL JOSEPH,PAMULAPATI GANAPATI REDDY,RACHAKONDA SUGUNA,ZHANG HAI-REN,CHUN BYOUNG-KWON,WANG PEIYUAN
申请号:
NZ59663510
公开号:
NZ596635A
申请日:
2010.05.20
申请国别(地区):
NZ
年份:
2014
代理人:
摘要:
Disclosed is a crystalline compound represented by the formula Sp-4 which is (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate / (S)-2-{ [(2R,3R,4R,SR)-S-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydrofuran-2-ylmethoxy]-phenoxyphosphorylamino} -propionic acid isopropyl ester. Further disclosed is a composition comprising the crystalline compound Sp-4 which is the (S) phosphorus enantiomer of the compound (S)-2-{ [(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino} -propionic acid isopropyl ester and a pharmaceutically acceptable medium for the treatment of a hepatitis C virus infection.